As of 2026-05-27, the Intrinsic Value of Medicamen Biotech Ltd (531146.BO) is 218.64 INR. This 531146.BO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 270.30 INR, the upside of Medicamen Biotech Ltd is -19.10%.
The range of the Intrinsic Value is 179.96 - 280.62 INR
Based on its market price of 270.30 INR and our intrinsic valuation, Medicamen Biotech Ltd (531146.BO) is overvalued by 19.10%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 179.96 - 280.62 | 218.64 | -19.1% |
| DCF (Growth 10y) | 224.42 - 336.50 | 268.01 | -0.8% |
| DCF (EBITDA 5y) | 395.29 - 674.90 | 520.76 | 92.7% |
| DCF (EBITDA 10y) | 374.42 - 646.26 | 491.91 | 82.0% |
| Fair Value | 57.45 - 57.45 | 57.45 | -78.75% |
| P/E | 387.03 - 551.01 | 490.71 | 81.5% |
| EV/EBITDA | 261.26 - 606.55 | 391.30 | 44.8% |
| EPV | 14.27 - 20.58 | 17.43 | -93.6% |
| DDM - Stable | 86.37 - 178.52 | 132.45 | -51.0% |
| DDM - Multi | 149.56 - 243.19 | 185.48 | -31.4% |
| Market Cap (mil) | 2,418.41 |
| Beta | |
| Outstanding shares (mil) | 8.95 |
| Enterprise Value (mil) | 2,552.84 |
| Market risk premium | 6.92% |
| Cost of Equity | 14.31% |
| Cost of Debt | 8.21% |
| WACC | 14.15% |